GS
RNTX

Gagnon Securities’s Rein Therapeutics RNTX Stock Holding History

Gagnon Securities’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Sell
239,520
-700
-0.3% -$868 0.07% 73
2025
Q4 		$279K Buy
240,220
+11,528
+5% +$15.9K 0.06% 76
2025
Q3 		$262K Buy
228,692
+156,947
+219% +$199K 0.05% 80
2025
Q2 		$100K Hold
71,745
– – 0.02% 86
2025
Q1 		$127K Hold
71,745
– – 0.03% 93
2024
Q4 		$165K Sell
71,745
-16
-0% -$48 0.03% 87
2024
Q3 		$254K Buy
71,761
+33,784
+89% +$90.3K 0.05% 78
2024
Q2 		$105K Buy
37,977
+30
+0.1% +$123 0.02% 90
2024
Q1 		$252K Hold
37,947
– – 0.06% 77
2023
Q4 		$116K Buy
+37,947
New +$74K 0.03% 98

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Gagnon Securities's RNTX Position: Q1 2026 in Review

Gagnon Securities reduced its Rein Therapeutics (RNTX) stake by 0.29% in Q1 2026, selling an estimated $868 and leaving 239,520 shares worth $311K. The position accounts for 0.07% of the portfolio, ranked #73.

Gagnon Securities first reported a position in RNTX in Q4 2023 and has held it in 10 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Gagnon Securities held 239,520 shares of Rein Therapeutics worth $311K as of Q1 2026.
  • Gagnon Securities sold 700 Rein Therapeutics shares in Q1 2026, an estimated $868.
  • Rein Therapeutics made up 0.07% of Gagnon Securities's portfolio in Q1 2026, its #73 holding.
  • Gagnon Securities first reported a position in Rein Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Gagnon Securities's 13F filing for Q1 2026, filed 22 Apr 2026.